A recent report from Elara Capital highlighted that Hantavirus, known for its low person-to-person transmission rate, is not expected to escalate to pandemic levels. The report emphasized that there have been no widely reported or officially confirmed deaths in India linked to the current Hantavirus outbreak. While individual cases of Hantavirus infections can be severe, outbreaks are usually localized and self-limiting.
Globally, Hantavirus infections are rare, and there are no specific USFDA-approved vaccines or antiviral treatments available. These rodent-borne RNA viruses primarily infect humans through the inhalation of aerosolized particles from rodent urine, droppings, or saliva. The report noted that only certain strains of Hantavirus, such as the Andes strain, have shown occasional person-to-person transmission.
In contrast to Hantavirus, which has limited spread, SARS-CoV-2, the virus responsible for COVID-19, spreads rapidly and has led to a pandemic. Two main clinical syndromes associated with Hantavirus have been identified globally. Hantavirus Pulmonary Syndrome in America can result in severe respiratory failure with mortality rates ranging from 40% to 50%.
Another syndrome, Hemorrhagic Fever with Renal Syndrome (HFRS), observed in Europe and Asia, affects the kidneys and blood vessels, with severe cases having mortality rates of up to 15%. A recent cluster linked to the Andes strain aboard a cruise ship in 2026 resulted in a small number of cases and three deaths, underscoring the disease’s limited spread.
The first recognized outbreak of Hantavirus Pulmonary Syndrome occurred in 1993 in the Four Corners region of the US, caused by the Sin Nombre virus, with 53 cases and 32 deaths, indicating a high fatality rate. China reported around 2.1 lakh HFRS cases from 2004 to 2019, with approximately 1,855 related deaths. Similarly, in the United States, there were a total of 864 reported Hantavirus infections between 1993 and 2022, resulting in approximately 302 deaths.
